Roche Holding AG isn’t done making moves in the obesity market after last month’s agreement to buy Carmot Therapeutics Inc. for as much as $3.1 billion (CHF2.64 billion).
This content was published on
2 minutes
Bloomberg
The Swiss drugmaker said on Tuesday that it’s on the hunt for additional biotech partners to help it challenge weight-loss leaders Novo Nordisk A/S and Eli Lilly & Co. Roche is looking for new ways of adjusting metabolism that could ultimately be combined with treatments it’s gaining in the Carmot deal.
“This is opening up a whole new vista for us,” James Sabry, Roche’s head of partnering, said in an interview on the sidelines of the JPMorgan Healthcare Conference in San Francisco.
More
More
Roche declares war on obesity with billion-dollar takeover
This content was published on
Pharmaceutical company Roche is entering the fight against obesity with the $2.7 billion takeover of United States firm Carmot Therapeutics.
Carmot was one in a flurry of recent deals Roche has made to bolster its pipeline. The company is also interested in oncology, neurology and ophthalmology as well as cardiovascular medicine, Sabry said.
While many companies are trying to break into the hot weight-loss market, Sabry said Roche is one of only a handful of suitors with the size and global reach to run the large, costly trials necessary to bring new drugs to market. Marketing obesity medicines is also more complicated than other areas like cancer because drugmakers need to deal with primary-care doctors instead of a few specialised treatment centres, he said.
More
More
What lies ahead for Switzerland: the economic outlook for 2024
This content was published on
SWI swissinfo.ch journalists select the major developments that await the Swiss economy in 2024.
“When we’re trying to get a deal done, we find more competitors in oncology,” he said. “You’d think everyone must be competing with you for metabolism drugs, but it’s not that way.”
Roche was one of the first pharmaceutical companies to work on an experimental drug in the GLP-1 class, a category that includes Novo’s Wegovy and Lilly’s Zepbound. But it halted development more than a decade ago after patients dropped out of a study due to side effects such as nausea.
What factors should be taken into account when inheriting Swiss citizenship abroad?
Should there be a limit to the passing on of Swiss citizenship? Or is the current practice too strict and it should still be possible to register after the age of 25?
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
This content was published on
Swiss imports and exports reached new heights in the first quarter, driven by the chemicals and pharmaceuticals sectors. Shipments to the US rose sharply.
Italian in Switzerland accused of being Calabrian mafia henchman
This content was published on
The Office of the Attorney General of Switzerland has charged an Italian resident of the Anello-Fruci 'Ndrangheta clan in the canton of Aargau.
Swiss CFOs have a pessimistic outlook due to trade wars
This content was published on
In the wake of the trade wars launched by US President Donald Trump, Swiss companies are assessing the future much more pessimistically.
Swiss parcel bomber had links to military and intelligence services
This content was published on
The 61-year-old man who admitted to being Patek Philippe's blackmailer in Geneva had connections in the police and the army.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.